Avrukibart vs SHR-1139

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

Avrukibart

Developed by Oruka Therapeutics

Phase 2 in Psoriasismonoclonal antibody
Partial signal

NCT07090330 · Phase 2 · active, not recruiting

This was a randomized, double-blind Phase 2 trial with 80 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: May 2030 · NCT07449702 (registry estimate)

Reported efficacy

Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). (met)

Result source: NCT07090330

SHR-1139

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Psoriasismonoclonal antibody (dual IL-23p19/IL-36R)
Weak signal

NCT07051538 · Phase 1 · completed

This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07719530 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAvrukibartSHR-1139
PASI 75—Not reported—Not reported
PASI 90—Not reported—Not reported
PASI 100—Not reported—Not reported
sPGA 0/1—Not reported—Not reported
DLQI, change—Not reported—Not reported

PASI 75

Avrukibart
—Not reported
SHR-1139
—Not reported

PASI 90

Avrukibart
—Not reported
SHR-1139
—Not reported

PASI 100

Avrukibart
—Not reported
SHR-1139
—Not reported

sPGA 0/1

Avrukibart
—Not reported
SHR-1139
—Not reported

DLQI, change

Avrukibart
—Not reported
SHR-1139
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1139: no structured comparison results are available for Psoriasis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Avrukibart
Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). NCT07090330 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avrukibart's landscape · SHR-1139's landscape